NM
TEVA icon

Nokota Management’s Teva Pharmaceuticals TEVA Stock Holding History

Nokota Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-666,712
Closed -$30.7M – 76
2016
Q3 		$30.7M Buy
+666,712
New +$34.8M 0.53% 28

Other funds holding TEVA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Nokota Management's TEVA Position: Q4 2016 in Review

Nokota Management sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 666,712 shares — an estimated $30.7M sold.

Nokota Management first reported a position in TEVA in Q3 2016 and held it in 1 quarter. The position peaked at $30.7M in Q3 2016. 739 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

  • Nokota Management reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Nokota Management sold 666,712 Teva Pharmaceuticals shares in Q4 2016, an estimated $30.7M.
  • Nokota Management first reported a position in Teva Pharmaceuticals in Q3 2016 and held it in 1 quarter.
  • Nokota Management's Teva Pharmaceuticals position peaked at $30.7M in Q3 2016.
  • 739 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Nokota Management's 13F filing for Q4 2016, filed 14 Feb 2017.